DK1761551T3 - Nanopartikler af gemcitabinderivater - Google Patents

Nanopartikler af gemcitabinderivater

Info

Publication number
DK1761551T3
DK1761551T3 DK05857322.1T DK05857322T DK1761551T3 DK 1761551 T3 DK1761551 T3 DK 1761551T3 DK 05857322 T DK05857322 T DK 05857322T DK 1761551 T3 DK1761551 T3 DK 1761551T3
Authority
DK
Denmark
Prior art keywords
nanoparticles
derivatives
difluoro
hydrogen
new
Prior art date
Application number
DK05857322.1T
Other languages
English (en)
Inventor
Flavio Rocco
Luigi Cattel
Barbara Stella
Veronique Rosilio
Jack-Michel Renoir
Patrick Couvreur
Original Assignee
Centre Nat Rech Scient
Univ Paris Sud 11
Flavio Rocco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Paris Sud 11, Flavio Rocco filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1761551T3 publication Critical patent/DK1761551T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05857322.1T 2004-06-30 2005-06-23 Nanopartikler af gemcitabinderivater DK1761551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0451365A FR2874016B1 (fr) 2004-06-30 2004-06-30 Nanoparticules de derives de la gemcitabine
PCT/FR2005/050488 WO2006090029A1 (fr) 2004-06-30 2005-06-23 Nanoparticules de derives de la gemcitabine

Publications (1)

Publication Number Publication Date
DK1761551T3 true DK1761551T3 (da) 2011-11-28

Family

ID=34945701

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05857322.1T DK1761551T3 (da) 2004-06-30 2005-06-23 Nanopartikler af gemcitabinderivater
DK09152764.8T DK2055711T3 (da) 2004-06-30 2005-06-23 Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09152764.8T DK2055711T3 (da) 2004-06-30 2005-06-23 Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand

Country Status (11)

Country Link
US (2) US7704972B2 (da)
EP (3) EP1925624A1 (da)
JP (2) JP4927726B2 (da)
CN (2) CN102335436B (da)
AT (2) ATE519773T1 (da)
CA (2) CA2805761C (da)
DK (2) DK1761551T3 (da)
ES (2) ES2371411T3 (da)
FR (1) FR2874016B1 (da)
PT (2) PT2055711E (da)
WO (1) WO2006090029A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007435B1 (en) * 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
FR2931152B1 (fr) * 2008-05-16 2010-07-30 Centre Nat Rech Scient Nouveau systeme de transfert d'acide nucleique
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
FR2937537A1 (fr) * 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
US9517476B2 (en) * 2008-10-31 2016-12-13 Hitachi Koki Co., Ltd. Centrifuge with acceleration and deceleration time display
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
US9693957B2 (en) 2011-07-08 2017-07-04 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
JP6420247B2 (ja) 2012-11-13 2018-11-07 ボーイエン セラピューティクス,インコーポレイティド ゲムシタビンプロドラッグ及びその使用
EP2742955A1 (en) 2012-12-12 2014-06-18 Centre National De La Recherche Scientifique Nanoparticles based on bioconjugate of GAG
WO2015037659A1 (ja) * 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 水溶液製剤及びその製造方法
CN105873569B (zh) 2013-11-06 2020-07-28 芝加哥大学 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
CN104693256B (zh) * 2013-12-04 2018-07-10 杭州源昶医药科技有限公司 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途
US10463684B2 (en) * 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
CN105030682B (zh) * 2015-06-24 2018-02-09 广州复大医疗股份有限公司 一种纳米微粒胶体及其制备方法与用途
JP7090034B2 (ja) 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
TWI719182B (zh) * 2017-03-29 2021-02-21 國立交通大學 奈米組成物、其製造方法及其用途
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
SG11202008346PA (en) * 2018-03-02 2020-09-29 January Therapeutics Inc Nanoparticle compositions
US20210238214A1 (en) * 2018-04-26 2021-08-05 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
WO2020247912A1 (en) * 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine

Also Published As

Publication number Publication date
US8044034B2 (en) 2011-10-25
CA2572380C (fr) 2013-11-19
JP4927726B2 (ja) 2012-05-09
CN102335436B (zh) 2014-10-08
JP5552473B2 (ja) 2014-07-16
US7704972B2 (en) 2010-04-27
CN101061131A (zh) 2007-10-24
JP2008504353A (ja) 2008-02-14
CN101061131B (zh) 2011-10-05
JP2012102107A (ja) 2012-05-31
US20090130214A1 (en) 2009-05-21
EP2055711B1 (fr) 2011-08-17
CN102335436A (zh) 2012-02-01
ES2372141T3 (es) 2012-01-16
EP1925624A1 (fr) 2008-05-28
EP1761551A1 (fr) 2007-03-14
ES2371411T3 (es) 2012-01-02
CA2805761C (fr) 2016-10-04
FR2874016A1 (fr) 2006-02-10
EP2055711A1 (fr) 2009-05-06
ATE519773T1 (de) 2011-08-15
CA2572380A1 (fr) 2006-08-31
CA2805761A1 (fr) 2006-08-31
WO2006090029A1 (fr) 2006-08-31
DK2055711T3 (da) 2011-12-12
EP1761551B1 (fr) 2011-08-10
ATE520703T1 (de) 2011-09-15
FR2874016B1 (fr) 2006-11-24
US20100160249A1 (en) 2010-06-24
PT1761551E (pt) 2011-11-24
PT2055711E (pt) 2011-12-07

Similar Documents

Publication Publication Date Title
DK1761551T3 (da) Nanopartikler af gemcitabinderivater
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
NO20071853L (no) Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.
MX2009011823A (es) Piridonacarboxamidas, agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion.
JP2003503348A5 (da)
MX2007008557A (es) Derivados de purina que actuan como agonistas del receptor a2a.
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
ATE503775T1 (de) Lagerstabile beschleunigerlösung
TW200635924A (en) Chemical compounds
RU2010120715A (ru) Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
WO2007119001A3 (fr) Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
JP2002519355A5 (da)
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
ES2054949T3 (es) Precursores de dopamina.
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
EP1224932A4 (en) DRUGS INHIBITING CELL DEATH
EA201071098A1 (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
AR063894A1 (es) Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica
ES2147966T3 (es) Derivados de guanidina sustituida y su uso como inhibidores del intercambio de na+/h+.
Henderson et al. Benzimidazole-containing HCV NS5A inhibitors: Effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency